OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.92 and trades as high as $5.97. OraSure Technologies shares last traded at $5.75, with a volume of 447,667 shares.
Wall Street Analyst Weigh In
OSUR has been the subject of several analyst reports. StockNews.com initiated coverage on OraSure Technologies in a research report on Thursday, March 16th. They set a “hold” rating for the company. Evercore ISI assumed coverage on OraSure Technologies in a research report on Tuesday, January 3rd. They set a $5.00 price objective for the company.
OraSure Technologies Stock Down 1.2 %
The stock has a market capitalization of $421.19 million, a price-to-earnings ratio of -22.12 and a beta of 0.08. The business has a 50-day simple moving average of $5.73 and a two-hundred day simple moving average of $4.92.
OraSure Technologies (NASDAQ:OSUR – Get Rating) last released its earnings results on Tuesday, February 14th. The medical instruments supplier reported $0.21 earnings per share for the quarter. The firm had revenue of $123.08 million during the quarter, compared to the consensus estimate of $96.88 million. OraSure Technologies has a negative return on equity of 0.42% and a negative net margin of 4.63%. The firm’s revenue for the quarter was up 93.6% compared to the same quarter last year. During the same period in the prior year, the firm posted earnings per share ($0.14). On average, analysts forecast that OraSure Technologies, Inc. will post 0.39 EPS for the current year.
Institutional Investors Weigh In On OraSure Technologies
A number of institutional investors have recently added to or reduced their stakes in OSUR. FMR LLC increased its holdings in shares of OraSure Technologies by 249.6% in the second quarter. FMR LLC now owns 10,687 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 7,630 shares in the last quarter. 1832 Asset Management LP bought a new position in shares of OraSure Technologies in the first quarter valued at $40,000. UBS Group AG increased its holdings in shares of OraSure Technologies by 82.3% in the third quarter. UBS Group AG now owns 11,217 shares of the medical instruments supplier’s stock valued at $42,000 after buying an additional 5,064 shares in the last quarter. Archon Capital Management LLC bought a new position in shares of OraSure Technologies in the fourth quarter valued at $48,000. Finally, Canandaigua National Corp bought a new position in shares of OraSure Technologies in the third quarter valued at $49,000. 85.62% of the stock is currently owned by institutional investors and hedge funds.
About OraSure Technologies
(Get Rating)
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices.
Featured Stories
Receive News & Ratings for OraSure Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OraSure Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.